About 50% undervalued: a profitable rare-disease company the market still doubts

Many biotech companies are valued mainly on future promises. Here, the company already sells approved treatments and is profitable, yet the share price reflects worry that too much revenue depends on a small number of products. Investors want proof that growth can continue even if one product slows.

The key question is whether the company can build a second strong growth driver from its newer treatment and keep advancing what comes next. If it shows that revenue can become more diversified, the stock can be valued more like a high-quality healthcare business, not like a risky biotech story.

Top points of analysis

• Two FDA-approved therapies form a clear growth framework: stable foundation + new engine.

• 2024 revenue grew to $491.7 million. USD and for 2021-2024 this implies a very fast growth rate (high "commercial CAGR" from a low base).

• The gross margin is extremely high and the TTM net margin of ~37% shows that this is not a "powerpoint story" but a cash business.

• The company has high…